Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

VoLumen

&times

Overview

What is VoLumen?

VoLumen is a barium sulfate suspension 0.1% w/v, 0.1% w/w for oral administration. Each 100 mL contains 0.1 g barium sulfate. Barium sulfate, due to its high molecular density is opaque to x-rays and therefore, acts as a positive contrast agent for radiographic studies. The active ingredient is barium sulfate and its structural formula is BaSO. Barium sulfate occurs as a fine, white, odorless, tasteless, bulky powder which is free from grittiness. Its aqueous suspensions are neutral to litmus. It is practically insoluble in water, solutions of acids and alkalies, and organic solvents.



What does VoLumen look like?



What are the available doses of VoLumen?

Sorry No records found.

What should I talk to my health care provider before I take VoLumen?

Sorry No records found

How should I use VoLumen?

For use in Computed Tomography to opacify the GI tract.

The volume of the CT barium sulfate suspension to be administered will depend on the degree and extent of contrast required in the area(s) under examination and on the technique employed.


What interacts with VoLumen?

This product should not be used in patients with known or suspected gastrointestinal perforation or hypersensitivity to barium sulfate or any component of this barium sulfate formulation.



What are the warnings of VoLumen?

Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases, particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chickenpox, prophylaxis with varicella-zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chickenpox develops, treatment with antiviral agents may be considered.


What are the precautions of VoLumen?

General

Diagnostic procedures which involve the use of radiopaque contrast agents should be carried out under the direction of personnel with the requisite training and with a thorough knowledge of the particular procedure to be performed. A history of bronchial asthma, atopy, as evidenced by hay fever and eczema, or a previous reaction to a contrast agent, warrant special attention. Caution should be exercised with the use of radiopaque media in severely debilitated patients and in those with marked hypertension or advanced cardiac disease. Ingestion of barium is not recommended in patients with a history of food aspiration. If barium studies are required in these patients or in patients in whom integrity of the swallowing mechanism is unknown, proceed with caution. If barium is aspirated into the larynx, further administration should be immediately discontinued.

Information for Patients

  • Inform their physician if they are pregnant.
  • Inform their physician if they are allergic to any drugs or food, or if they have had any prior reactions to barium sulfate products or other contrast agents used in x-ray procedures (see ).
  • Inform their physician about any other medications they are currently taking.
  • Seek immediate medical attention if they experience an allergic reaction after using this product.


Before administration of this product, patients receiving barium sulfate diagnostic agents should be instructed to:

Drug Interactions

The presence of barium sulfate formulations in the GI tract may alter the absorption of therapeutic agents taken concomitantly. In order to minimize any potential change in absorption, the separate administration of barium sulfate from that of other agents should be considered.

Usage in Pregnancy

Radiation is known to cause harm to the unborn fetus exposed in utero. Therefore, radiographic procedures should only be used when, in the judgement of the physician, its use is deemed essential to the welfare of the pregnant patient.

Nursing Mothers

Barium sulfate products may be used during lactation.


What are the side effects of VoLumen?

Sorry No records found


What should I look out for while using VoLumen?

This product should not be used in patients with known or suspected gastrointestinal perforation or hypersensitivity to barium sulfate or any component of this barium sulfate formulation.

Rarely, severe allergic reactions of an anaphylactoid nature, have been reported following administration of barium sulfate contrast agents. Appropriately trained personnel and facilities should be available for emergency treatment of severe reactions and should remain available for at least 30 to 60 minutes following administration, since delayed reactions can occur.


What might happen if I take too much VoLumen?

On rare occasions following repeated administration, severe stomach cramps, nausea, vomiting, diarrhea or constipation may occur. These indicated responses can be present in both fluoroscopic and CT procedures. These are transitory in nature and are not considered serious. Symptoms may be treated according to currently accepted standards of medical care.


How should I store and handle VoLumen?

Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the USP/NF with a child-resistant closure.A Schedule CII Narcotic.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the USP/NF with a child-resistant closure.A Schedule CII Narcotic.Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the USP/NF with a child-resistant closure.A Schedule CII Narcotic.VoLumen is supplied in the following quantity: 450 mL bottles,Cat. No. 9450, NDC 32909-945-03Rx Only (USA)SHAKE WELL PRIOR TO USEPatent PendingManufactured by E-Z-EM Canada Inc.for E-Z-EM, Inc.a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel: 1-516-333-8230 1-800 544-4624rev. 05/14 TX1272-3  ©2006 E-Z-EM, Inc.VoLumen is supplied in the following quantity: 450 mL bottles,Cat. No. 9450, NDC 32909-945-03Rx Only (USA)SHAKE WELL PRIOR TO USEPatent PendingManufactured by E-Z-EM Canada Inc.for E-Z-EM, Inc.a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel: 1-516-333-8230 1-800 544-4624rev. 05/14 TX1272-3  ©2006 E-Z-EM, Inc.VoLumen is supplied in the following quantity: 450 mL bottles,Cat. No. 9450, NDC 32909-945-03Rx Only (USA)SHAKE WELL PRIOR TO USEPatent PendingManufactured by E-Z-EM Canada Inc.for E-Z-EM, Inc.a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel: 1-516-333-8230 1-800 544-4624rev. 05/14 TX1272-3  ©2006 E-Z-EM, Inc.VoLumen is supplied in the following quantity: 450 mL bottles,Cat. No. 9450, NDC 32909-945-03Rx Only (USA)SHAKE WELL PRIOR TO USEPatent PendingManufactured by E-Z-EM Canada Inc.for E-Z-EM, Inc.a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel: 1-516-333-8230 1-800 544-4624rev. 05/14 TX1272-3  ©2006 E-Z-EM, Inc.VoLumen is supplied in the following quantity: 450 mL bottles,Cat. No. 9450, NDC 32909-945-03Rx Only (USA)SHAKE WELL PRIOR TO USEPatent PendingManufactured by E-Z-EM Canada Inc.for E-Z-EM, Inc.a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel: 1-516-333-8230 1-800 544-4624rev. 05/14 TX1272-3  ©2006 E-Z-EM, Inc.VoLumen is supplied in the following quantity: 450 mL bottles,Cat. No. 9450, NDC 32909-945-03Rx Only (USA)SHAKE WELL PRIOR TO USEPatent PendingManufactured by E-Z-EM Canada Inc.for E-Z-EM, Inc.a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel: 1-516-333-8230 1-800 544-4624rev. 05/14 TX1272-3  ©2006 E-Z-EM, Inc.


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Barium sulfate, due to its high molecular density is opaque to x-rays and, therefore, acts as a positive contrast agent for radiographic studies. Barium sulfate is biologically inert and, therefore, is not absorbed or metabolized by the body, and is eliminated from the GI tract unchanged.

Non-Clinical Toxicology
This product should not be used in patients with known or suspected gastrointestinal perforation or hypersensitivity to barium sulfate or any component of this barium sulfate formulation.

Rarely, severe allergic reactions of an anaphylactoid nature, have been reported following administration of barium sulfate contrast agents. Appropriately trained personnel and facilities should be available for emergency treatment of severe reactions and should remain available for at least 30 to 60 minutes following administration, since delayed reactions can occur.

The presence of barium sulfate formulations in the GI tract may alter the absorption of therapeutic agents taken concomitantly. In order to minimize any potential change in absorption, the separate administration of barium sulfate from that of other agents should be considered.

Diagnostic procedures which involve the use of radiopaque contrast agents should be carried out under the direction of personnel with the requisite training and with a thorough knowledge of the particular procedure to be performed. A history of bronchial asthma, atopy, as evidenced by hay fever and eczema, or a previous reaction to a contrast agent, warrant special attention. Caution should be exercised with the use of radiopaque media in severely debilitated patients and in those with marked hypertension or advanced cardiac disease. Ingestion of barium is not recommended in patients with a history of food aspiration. If barium studies are required in these patients or in patients in whom integrity of the swallowing mechanism is unknown, proceed with caution. If barium is aspirated into the larynx, further administration should be immediately discontinued.

Adverse reactions, such as nausea, vomiting, diarrhea and abdominal cramping, accompanying the use of barium sulfate formulations are infrequent and usually mild. Severe reactions (approximately 1 in 1,000,000) and fatalities (approximately 1 in 10,000,000) have occurred. Procedural complications are rare, but may include aspiration pneumonitis, granuloma formation, intravasation, embolization and peritonitis following intestinal perforation, vasovagal and syncopal episodes, and fatalities.

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).